Otsuka Holdings Co., Ltd. (OTSKY)
USD 27.55
(-0.4%)
USD 27.55
(-0.4%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1407.34 Billion JPY | 20.44% |
| 2022 | 1168.49 Billion JPY | 16.47% |
| 2021 | 1003.24 Billion JPY | 2.05% |
| 2020 | 983.07 Billion JPY | 4.04% |
| 2019 | 944.94 Billion JPY | 11.15% |
| 2018 | 850.15 Billion JPY | 4.0% |
| 2017 | 817.47 Billion JPY | 3.58% |
| 2016 | 789.21 Billion JPY | -20.76% |
| 2015 | 995.95 Billion JPY | -12.67% |
| 2014 | 1140.49 Billion JPY | 38.37% |
| 2013 | 824.22 Billion JPY | 7.7% |
| 2012 | 765.31 Billion JPY | 5.83% |
| 2011 | 723.12 Billion JPY | -0.63% |
| 2010 | 727.68 Billion JPY | 14.89% |
| 2009 | 633.35 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 425 Billion JPY | 15.58% |
| 2024 Q1 | 367.71 Billion JPY | -1.58% |
| 2023 Q4 | 373.62 Billion JPY | -0.11% |
| 2023 Q1 | 311.56 Billion JPY | -5.41% |
| 2023 Q2 | 348.1 Billion JPY | 11.73% |
| 2023 Q3 | 374.05 Billion JPY | 7.45% |
| 2023 FY | 1407.34 Billion JPY | 20.44% |
| 2022 Q3 | 299.08 Billion JPY | 4.56% |
| 2022 Q4 | 329.39 Billion JPY | 10.13% |
| 2022 FY | 1168.49 Billion JPY | 16.47% |
| 2022 Q1 | 253.96 Billion JPY | -0.21% |
| 2022 Q2 | 286.05 Billion JPY | 12.63% |
| 2021 FY | 1003.24 Billion JPY | 2.05% |
| 2021 Q3 | 265.14 Billion JPY | 3.25% |
| 2021 Q4 | 254.49 Billion JPY | -4.01% |
| 2021 Q2 | 256.79 Billion JPY | 13.22% |
| 2021 Q1 | 226.81 Billion JPY | -7.28% |
| 2020 Q3 | 258.55 Billion JPY | 5.25% |
| 2020 Q2 | 245.66 Billion JPY | 4.88% |
| 2020 FY | 983.07 Billion JPY | 4.04% |
| 2020 Q1 | 234.23 Billion JPY | -5.44% |
| 2020 Q4 | 244.62 Billion JPY | -5.38% |
| 2019 Q3 | 242.95 Billion JPY | -0.94% |
| 2019 FY | 944.94 Billion JPY | 11.15% |
| 2019 Q4 | 247.71 Billion JPY | 1.96% |
| 2019 Q2 | 245.26 Billion JPY | 17.35% |
| 2019 Q1 | 209 Billion JPY | -7.65% |
| 2018 Q3 | 217.01 Billion JPY | 2.03% |
| 2018 Q2 | 212.7 Billion JPY | 9.57% |
| 2018 Q4 | 226.31 Billion JPY | 4.29% |
| 2018 FY | 850.15 Billion JPY | 4.0% |
| 2018 Q1 | 194.12 Billion JPY | -7.12% |
| 2017 Q3 | 213.3 Billion JPY | 1.37% |
| 2017 FY | 817.47 Billion JPY | 3.58% |
| 2017 Q4 | 209.01 Billion JPY | -2.01% |
| 2017 Q2 | 210.42 Billion JPY | 13.91% |
| 2017 Q1 | 184.72 Billion JPY | 2.03% |
| 2016 Q2 | 205.53 Billion JPY | 9.18% |
| 2016 Q4 | 181.06 Billion JPY | -11.01% |
| 2016 FY | 789.21 Billion JPY | -20.76% |
| 2016 Q3 | 203.46 Billion JPY | -1.01% |
| 2016 Q1 | 188.24 Billion JPY | -15.67% |
| 2015 FY | 995.95 Billion JPY | -12.67% |
| 2015 Q4 | 223.22 Billion JPY | -7.78% |
| 2015 Q3 | 242.05 Billion JPY | -5.14% |
| 2015 Q2 | 255.16 Billion JPY | -7.39% |
| 2015 Q1 | 275.51 Billion JPY | 0.0% |
| 2014 Q2 | 273.28 Billion JPY | 4.11% |
| 2014 Q1 | 262.49 Billion JPY | -0.78% |
| 2014 FY | 1140.49 Billion JPY | 38.37% |
| 2014 Q3 | 293.63 Billion JPY | 7.45% |
| 2013 Q1 | 226.83 Billion JPY | 16.23% |
| 2013 Q2 | 225.07 Billion JPY | -0.78% |
| 2013 Q4 | 264.54 Billion JPY | 2.14% |
| 2013 Q3 | 259 Billion JPY | 15.08% |
| 2013 FY | 824.22 Billion JPY | 7.7% |
| 2012 Q4 | 195.15 Billion JPY | -5.64% |
| 2012 FY | 765.31 Billion JPY | 5.83% |
| 2012 Q3 | 206.81 Billion JPY | 5.83% |
| 2012 Q2 | 195.42 Billion JPY | 9.09% |
| 2012 Q1 | 179.14 Billion JPY | -7.15% |
| 2011 Q3 | 199.04 Billion JPY | 2.51% |
| 2011 Q4 | 192.94 Billion JPY | -3.07% |
| 2011 Q2 | 194.17 Billion JPY | 16.28% |
| 2011 Q1 | 166.99 Billion JPY | -4.39% |
| 2011 FY | 723.12 Billion JPY | -0.63% |
| 2010 Q4 | 174.65 Billion JPY | -9.46% |
| 2010 Q1 | 177.81 Billion JPY | -0.46% |
| 2010 Q2 | 188.56 Billion JPY | 6.04% |
| 2010 Q3 | 192.91 Billion JPY | 2.31% |
| 2010 FY | 727.68 Billion JPY | 14.89% |
| 2009 Q2 | 174.29 Billion JPY | 0.0% |
| 2009 Q4 | 178.63 Billion JPY | -9.29% |
| 2009 Q3 | 196.93 Billion JPY | 12.99% |
| 2009 FY | 633.35 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | -3956.558% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | -4001.504% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | -4569.656% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -12524141.346% |
| Novartis AG | 34.18 Billion USD | -4016.5% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -189193.857% |